Jyotishman Pathak1, Christopher G Chute. 1. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota 55905, USA. pathak.jyotishman@mayo.edu
Abstract
BACKGROUND: The RxNorm and NDF-RT (National Drug File Reference Terminology) are a suite of terminology standards for clinical drugs designated for use in the US federal government systems for electronic exchange of clinical health information. Analyzing how different drug products described in these terminologies are categorized into drug classes will help in their better organization and classification of pharmaceutical information. METHODS: Mappings between drug products in RxNorm and NDF-RT drug classes were extracted. Mappings were also extracted between drug products in RxNorm to five high-level NDF-RT categories: Chemical Structure; cellular or subcellular Mechanism of Action; organ-level or system-level Physiologic Effect; Therapeutic Intent; and Pharmacokinetics. Coverage for the mappings and the gaps were evaluated and analyzed algorithmically. RESULTS: Approximately 54% of RxNorm drug products (Semantic Clinical Drugs) were found not to have a correspondence in NDF-RT. Similarly, approximately 45% of drug products in NDF-RT are missing from RxNorm, most of which can be attributed to differences in dosage, strength, and route form. Approximately 81% of Chemical Structure classes, 42% of Mechanism of Action classes, 75% of Physiologic Effect classes, 76% of Therapeutic Intent classes, and 88% of Pharmacokinetics classes were also found not to have any RxNorm drug products classified under them. Finally, various issues regarding inconsistent mappings between drug concepts were identified in both terminologies. CONCLUSION: This investigation identified potential limitations of the existing classification systems and various issues in specification of correspondences between the concepts in RxNorm and NDF-RT. These proposals and methods provide the preliminary steps in addressing some of the requirements.
BACKGROUND: The RxNorm and NDF-RT (National Drug File Reference Terminology) are a suite of terminology standards for clinical drugs designated for use in the US federal government systems for electronic exchange of clinical health information. Analyzing how different drug products described in these terminologies are categorized into drug classes will help in their better organization and classification of pharmaceutical information. METHODS: Mappings between drug products in RxNorm and NDF-RT drug classes were extracted. Mappings were also extracted between drug products in RxNorm to five high-level NDF-RT categories: Chemical Structure; cellular or subcellular Mechanism of Action; organ-level or system-level Physiologic Effect; Therapeutic Intent; and Pharmacokinetics. Coverage for the mappings and the gaps were evaluated and analyzed algorithmically. RESULTS: Approximately 54% of RxNorm drug products (Semantic Clinical Drugs) were found not to have a correspondence in NDF-RT. Similarly, approximately 45% of drug products in NDF-RT are missing from RxNorm, most of which can be attributed to differences in dosage, strength, and route form. Approximately 81% of Chemical Structure classes, 42% of Mechanism of Action classes, 75% of Physiologic Effect classes, 76% of Therapeutic Intent classes, and 88% of Pharmacokinetics classes were also found not to have any RxNorm drug products classified under them. Finally, various issues regarding inconsistent mappings between drug concepts were identified in both terminologies. CONCLUSION: This investigation identified potential limitations of the existing classification systems and various issues in specification of correspondences between the concepts in RxNorm and NDF-RT. These proposals and methods provide the preliminary steps in addressing some of the requirements.
Authors: Stuart J Nelson; Steven H Brown; Mark S Erlbaum; Nels Olson; Tammy Powell; Brian Carlsen; John Carter; Mark S Tuttle; William T Hole Journal: Proc AMIA Symp Date: 2002
Authors: S Trent Rosenbloom; Joseph Awad; Ted Speroff; Peter L Elkin; Russell Rothman; Anderson Spickard; Josh Peterson; Brent A Bauer; Dietland L Wahner-Roedler; Mark Lee; William M Gregg; Kevin B Johnson; Jim Jirjis; Mark S Erlbaum; John S Carter; Michael J Lincoln; Steven H Brown Journal: AMIA Annu Symp Proc Date: 2003
Authors: John S Carter; Steven H Brown; Brent A Bauer; Peter L Elkin; Mark S Erlbaum; David A Froehling; Michael J Lincoln; S Trent Rosenbloom; Dietlind L Wahner-Roedler; Mark S Tuttle Journal: AMIA Annu Symp Proc Date: 2006
Authors: Omar Bouhaddou; Pradnya Warnekar; Fola Parrish; Nhan Do; Jack Mandel; John Kilbourne; Michael J Lincoln Journal: J Am Med Inform Assoc Date: 2007-12-20 Impact factor: 4.497
Authors: Jyotishman Pathak; Sean P Murphy; Brian N Willaert; Hilal M Kremers; Barbara P Yawn; Walter A Rocca; Christopher G Chute Journal: AMIA Annu Symp Proc Date: 2011-10-22
Authors: Himali Saitwal; David Qing; Stephen Jones; Elmer V Bernstam; Christopher G Chute; Todd R Johnson Journal: J Biomed Inform Date: 2012-06-28 Impact factor: 6.317
Authors: Suzette J Bielinski; Jennifer L St Sauver; Janet E Olson; Nicholas B Larson; John L Black; Steven E Scherer; Matthew E Bernard; Eric Boerwinkle; Bijan J Borah; Pedro J Caraballo; Timothy B Curry; HarshaVardhan Doddapaneni; Christine M Formea; Robert R Freimuth; Richard A Gibbs; Jyothsna Giri; Matthew A Hathcock; Jianhong Hu; Debra J Jacobson; Leila A Jones; Sara Kalla; Tyler H Koep; Viktoriya Korchina; Christie L Kovar; Sandra Lee; Hongfang Liu; Eric T Matey; Michaela E McGree; Tammy M McAllister; Ann M Moyer; Donna M Muzny; Wayne T Nicholson; Lance J Oyen; Xiang Qin; Ritika Raj; Véronique L Roger; Carolyn R Rohrer Vitek; Jason L Ross; Richard R Sharp; Paul Y Takahashi; Eric Venner; Kimberly Walker; Liwei Wang; Qiaoyan Wang; Jessica A Wright; Tsung-Jung Wu; Liewei Wang; Richard M Weinshilboum Journal: Int J Epidemiol Date: 2020-02-01 Impact factor: 7.196
Authors: Megan Hoopes; Heather Angier; Lewis A Raynor; Andrew Suchocki; John Muench; Miguel Marino; Pedro Rivera; Nathalie Huguet Journal: J Am Med Inform Assoc Date: 2018-10-01 Impact factor: 4.497